Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joinn Laboratories (China) CoHKSE:06127 +3.53%83 Piotroski F-Score is 6 as of Aug. 27, 2026, which is 20% above its 10-year median of 5.00. GuruFocus rates HKSE:06127 with a GF Score™ of 83/100 and a GF Value™ of HK$10.24 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 208 Medical Diagnostics & Research companies, Joinn Laboratories (China) Co ranks better than 78.85% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Joinn Laboratories (China) Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Joinn Laboratories (China) Co's Piotroski F-Score or its related term are showing as below:
HKSE:06127'
s Piotroski F-Score Range Over the Past 10 Years
Min: 3 Med: 5 Max: 9
Current: 6
During the past 13 years, the highest Piotroski F-Score of Joinn Laboratories (China) Co was 9. The lowest was 3. And the median was 5.
Joinn Laboratories (China) Co (HKSE:06127) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Joinn Laboratories (China) Co Piotroski F-Score Related Terms
Joinn Laboratories (China) Co Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joinn Laboratories (China) Co Piotroski F-Score Chart
HKSE:06127 vs TMO, DHR, IDXX: Piotroski F-Score Comparison
For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joinn Laboratories (China) Co Piotroski F-Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Joinn Laboratories (China) Co's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Mar26) TTM:
Last Year (Mar25) TTM:
Net Income was 21.657 + 21.609 + 239.874 + 270.683 = HK$554 Mil. Cash Flow from Operations was 106.709 + 113.236 + 196.836 + 144.917 = HK$562 Mil. Revenue was 416.716 + 345.753 + 743.108 + 359.009 = HK$1,865 Mil. Gross Profit was 85.735 + 56.433 + 144.754 + 73.546 = HK$360 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(10105.25 + 10355.052 + 10418.267 + 10695.848 + 11398.056) / 5 = HK$10594.4946 Mil. Total Assets at the begining of this year (Mar25) was HK$10,105 Mil. Long-Term Debt & Capital Lease Obligation was HK$14 Mil. Total Current Assets was HK$5,755 Mil. Total Current Liabilities was HK$1,433 Mil.
Net Income was 110.324 + 109.484 + 154.153 + 44.088 = HK$418 Mil.
Revenue was 564.698 + 534.888 + 729.41 + 308.087 = HK$2,137 Mil. Gross Profit was 162.861 + 119.982 + 220.868 + 88.14 = HK$592 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(10573.248 + 10400.782 + 10487.665 + 10032.01 + 10105.25) / 5 = HK$10319.791 Mil. Total Assets at the begining of last year (Mar24) was HK$10,573 Mil. Long-Term Debt & Capital Lease Obligation was HK$23 Mil. Total Current Assets was HK$5,429 Mil. Total Current Liabilities was HK$1,177 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Joinn Laboratories (China) Co's current Net Income (TTM) was 554.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Joinn Laboratories (China) Co's current Cash Flow from Operations (TTM) was 562.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Joinn Laboratories (China) Co's return on assets of this year was 0.05480547. Joinn Laboratories (China) Co's return on assets of last year was 0.03953837.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Joinn Laboratories (China) Co's gearing of this year was 0.0013373. Joinn Laboratories (China) Co's gearing of last year was 0.00218154.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Joinn Laboratories (China) Co's current ratio of this year was 4.01674467. Joinn Laboratories (China) Co's current ratio of last year was 4.61323789.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Joinn Laboratories (China) Co's number of shares in issue this year was 744.865. Joinn Laboratories (China) Co's number of shares in issue last year was 822.39.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Joinn Laboratories (China) Co's gross margin of this year was 0.19332334. Joinn Laboratories (China) Co's gross margin of last year was 0.27694338.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Joinn Laboratories (China) Co's asset turnover of this year was 0.18451656. Joinn Laboratories (China) Co's asset turnover of last year was 0.20212171.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
1
+
1
+
0
+
1
+
0
+
0
=
6
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Joinn Laboratories (China) Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.
Joinn Laboratories (China) Co (HKSE:06127) has a Piotroski F-Score of 6 as of Aug. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Joinn Laboratories (China) Co and its competitors. This is 20% above median its historical median of 5.00. Over the past decade, Joinn Laboratories (China) Co's Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, Joinn Laboratories (China) Co ranks #44 out of 208 companies in the Medical Diagnostics & Research industry, placing it in the top 21.2%.
Is Joinn Laboratories (China) Co's Piotroski F-Score too high?
Joinn Laboratories (China) Co's current Piotroski F-Score of 6 is 20% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Joinn Laboratories (China) Co's value of 6 is 20% above this industry median. Based on the distribution chart, Joinn Laboratories (China) Co ranks #44 out of 208 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Joinn Laboratories (China) Co has a GF Score™ of 83/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Joinn Laboratories (China) Co's Piotroski F-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Joinn Laboratories (China) Co ranks #44 out of 208 companies for Piotroski F-Score. This places Joinn Laboratories (China) Co in the top 21% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Joinn Laboratories (China) Co's value of 6 is 20% above this benchmark. Historically, Joinn Laboratories (China) Co's own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Joinn Laboratories (China) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Joinn Laboratories (China) Co's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Joinn Laboratories (China) Co and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Joinn Laboratories (China) Co's current Piotroski F-Score is 6, which is 20% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joinn Laboratories (China) Co stock overvalued right now?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co (HKSE:06127) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$10.24, compared to a current price of HK$25.82 — trading 152.1% above its estimated fair value. The current Piotroski F-Score is 6, which is 20% above median its 10-year median of 5.00 and 20% above the Medical Diagnostics & Research industry median of 5.00. Joinn Laboratories (China) Co's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Joinn Laboratories (China) Co (HKSE:06127), the current Piotroski F-Score is 6 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joinn Laboratories (China) Co (HKSE:06127) Overvalued in 2026?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co stock appears to be overvalued.
The current stock price of HK$25.82 is trading 152.1% above its estimated GF Value™ of HK$10.24.
GuruFocus considers Joinn Laboratories (China) Co to be Significantly Overvalued.
Key valuation signals for HKSE:06127:
Piotroski F-Score: 6 (20% above median its 10-year median of 5.00)
GF Value™: HK$10.24 vs. price of HK$25.82 (152.1% above fair value)
Industry Position: 20% above the Medical Diagnostics & Research median (#44 of 208)
No single metric tells the full story. See the HKSE:06127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
83GF Score
Get the complete analysis for HKSE:06127
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06127 has been successfully added to your 
